419 completed. 419 Phase 1, 79 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 419 | Completed 419 |
| Phase 2 | 79 | Completed 79 |
Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years Midazolam (MDZ), GSK3772701 - Malaria, Falciparum | Phase 1 | Completed | GlaxoSmithKline | 20 | 2026-06-26 | 2026-09-30 |
| First-in-Human Trial of Oral AN2-502998 AN2-502998, Placebo - Healthy Volunteers | Phase 1 | Completed | AN2 Therapeutics, Inc | 72 | 2025-08-04 | 2026-04-30 |
| Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso SUM-101 - Malaria,Falciparum | Phase 1 | Completed | European Vaccine Initiative | 39 | 2025-08-01 | 2026-09-11 |
| First-in-Human PfSPZ-LARC2 Vaccination/CHMI PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9% - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 2025-07-23 | 2026-08-17 |
| Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum Controlled Human Malaria Infection - Malaria (Plasmodium Falciparum) | Phase 1 | Completed | Centre de Recherche Médicale de Lambaréné | 20 | 2025-07-18 | 2026-09-11 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011 IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3 - Rift Valley Fever | Phase 1 | Completed | IDBiologics, Inc. | 40 | 2025-04-02 | 2026-11-10 |
| Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV - Healthy Volunteers | Phase 1 | Completed | Gates Medical Research Institute | 125 | 2025-03-28 | 2026-06-03 |
| Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso PfSPZ-LARC2 Vaccine, Normal Saline (Placebo) - Malaria Falciparum, Malaria Infection | Phase 1 | Completed | Sanaria Inc. | 75 | 2025-03-04 | 2026-04-16 |
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 161 | 2025-02-24 | 2026-09-11 |
| Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever N-pVAX1 - Crimean Congo Hemorrhagic Fever | Phase 1 | Completed | Karolinska Institutet | 15 | 2024-11-12 | 2026-03-23 |
| Trial of an Inactivated Chikungunya Virus Vaccine HydroVax-005 CHIKV, Placebo - Chikungunya Fever, Chikungunya Virus | Phase 1 | Completed | Najit Technologies, Inc. | 48 | 2024-11-04 | 2026-03-19 |
| Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184 - Zika Virus | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2024-09-24 | 2026-03-09 |
| Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants MMV371 LAI, Placebo for MMV371 - Malaria,Falciparum | Phase 1 | Completed | Medicines for Malaria Venture | 32 | 2024-08-27 | 2026-05-05 |
| L9LS MAb in Malian Infants L9LS, Placebo, R21/Matrix-MTM - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 327 | 2024-08-19 | 2026-10-01 |
| Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali TB31F, Normal saline - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 167 | 2024-07-12 | 2026-01-22 |
| A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults AVX70120 low dose level, AVX70120 middle dose level, AVX70120 high dose level - Yellow Fever, Rabies | Phase 1 | Completed | AstriVax Therapeutics | 112 | 2024-06-16 | 2026-04-22 |
| Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients CPLE, Placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 184 | 2024-06-01 | 2025-04-25 |
| A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants BAY 44-4400 - Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness) | Phase 1 | Completed | Bayer | 14 | 2024-05-07 | 2024-09-27 |
| A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) Plasmodium falciparum, MK-7602, Artemether/lumefantrine - Malaria | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2024-04-18 | 2025-01-13 |
| Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults VLA1601, CpG 1018®, 3M-052-AF - Zika, Zika Virus Infection | Phase 1 | Completed | Valneva Austria GmbH | 150 | 2024-03-25 | 2026-03-09 |
Showing 20 of 419. Sign in to see all of them.
Malaria (222) · Malaria, Falciparum (103) · Dengue (55) · Zika Virus Infection (21) · Severe Dengue (16) · Malaria, Vivax (15) · Chikungunya Fever (9) · Leishmaniasis (9) · Parasitemia (8) · Schistosomiasis (8) · Virus Diseases (8) · Chagas Disease (7) · Leishmaniasis, Cutaneous (7) · Infections (6) · Parasitic Diseases (6)
Infections (413) · Mosquito-Borne Diseases (368) · Parasitic Diseases (295) · Protozoan Infections (287) · RNA Virus Infections (109) · Virus Diseases (107) · Arbovirus Infections (105) · Flaviviridae Infections (89) · Flavivirus Infections (85) · Hemorrhagic Fevers, Viral (66) · Malaria (42) · Euglenozoa Infections (27) · Pathological Conditions, Signs and Symptoms (18) · Skin Diseases (15)
Saline Solution (17) · Artemether, Lumefantrine Drug Combination (12) · Aluminum Hydroxide (11) · Primaquine (11) · Chloroquine (9) · Sodium Chloride (9) · Vaccines (8) · Matrix-M (7) · Artesunate (6) · Rabies Vaccines (6) · Lumefantrine (5) · ProMune (5) · artefenomel (5) · atovaquone, proguanil drug combination (5) · fanasil, pyrimethamine drug combination (5)
National Institute of Allergy and Infectious Diseases (NIAID) (100) · University of Oxford (51) · Medicines for Malaria Venture (37) · U.S. Army Medical Research and Development Command (34) · Sanaria Inc. (20) · GlaxoSmithKline (12) · Drugs for Neglected Diseases (7) · Access to Advanced Health Institute (AAHI) (6) · Novartis Pharmaceuticals (6) · Bayer (5) · London School of Hygiene and Tropical Medicine (5) · Radboud University Medical Center (5) · European Vaccine Initiative (4) · ModernaTX, Inc. (4) · Pfizer (4)
United States (171) · United Kingdom (55) · Australia (23) · Mali (21) · Burkina Faso (12) · Netherlands (12) · Tanzania (10) · Switzerland (9) · France (7) · Kenya (7) · Thailand (7) · Uganda (7) · Belgium (6) · Colombia (6) · The Gambia (6)
Anna Durbin, MD (30) · Patrick E Duffy, M.D. (7) · Adrian V Hill, DPhill FRCP (5) · Adrian VS Hill, D.Phil, FRCP (5) · James McCarthy, Prof (5) · Adrian V S Hill, MD (4) · Kristen Pierce, MD (4) · Ulrike Lorch, MD FRCA FFPM (4) · Adrian VS Hill (3) · Adrian VS Hill, MA, BM BCh, DPhil, DM (3)
PMID 39787798, PMID 26383952, PMID 29217375, PMID 40245769, PMID 41014333, PMID 23526949, PMID 23899517, PMID 25211344, PMID 25801652, PMID 26292027, PMID 26292257, PMID 26424605, PMID 26458804, PMID 27695088, PMID 29389671, PMID 31932368, PMID 32239164, PMID 32275867, PMID 32394880, PMID 32572470, PMID 33717176, PMID 34194041, PMID 34265407, PMID 36682364, PMID 37971871, PMID 39324693, PMID 39708824, PMID 39805302, PMID 41176969, PMID 42253092, PMID 10190913, PMID 10501745, PMID 12663340, PMID 12742586, PMID 1313024, PMID 15069048, PMID 16904798, PMID 17075340, PMID 17428147, PMID 17940609, PMID 18190252, PMID 18213374, PMID 18231580, PMID 18253503, PMID 18270560, PMID 18337339, PMID 18378716, PMID 18545693, PMID 18612426, PMID 18698359
2019 (4), 2016 (3), 2015 (2), 2018 (2), U01CI000211 (2), 2014 (1), 2023 (1), 5UM1AI148373-03 (1), 5UM1AI148684-04 (1), N01AI085346 (1), R01AI025136 (1), R01HL086488 (1), R01NS074409 (1), U01AI065683 (1), U01AI066050 (1)